Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Rheumatic disease in pregnancy and breastfeeding

Rheumatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Maternal or obstetric deterioration

New hypertension, neurological symptoms, chest pain, dyspnoea, thrombosis, fever, reduced fetal movement, bleeding or rapidly active renal, cardiac, pulmonary or neurological rheumatic disease may threaten both mother and fetus.

Action: Arrange urgent obstetric and specialty assessment, stabilise the mother using pregnancy-compatible emergency treatment, investigate infection, pre-eclampsia, thrombosis and disease flare in parallel, and do not withhold organ-saving therapy solely because of pregnancy.

Synopsis

Plan conception and postnatal care around stable rheumatic disease, replace teratogenic medicines before pregnancy, continue compatible disease control, and coordinate maternal, placental, fetal and infant-vaccine monitoring.

  • Aim for stable low disease activity for about six months before conception, using medicines that can continue through pregnancy; active disease is itself a maternal and fetal exposure.
  • At preconception review define renal, cardiac, pulmonary and thrombotic risk, check blood pressure and urine, and test anti-Ro, anti-La and antiphospholipid antibodies when relevant.
  • Hydroxychloroquine, sulfasalazine with folic acid 5 mg daily, azathioprine, tacrolimus, ciclosporin, prednisolone, colchicine and TNF inhibitors can be compatible when clinically indicated.
  • Methotrexate is incompatible: stop at least one month before maternal conception. Mycophenolate requires at least six weeks, and leflunomide requires accelerated elimination with verified teriflunomide levels.
  • Use NSAIDs cautiously earlier in pregnancy, avoid systemic use from 20 weeks unless clinically necessary and stop by 30 weeks; low-dose aspirin for obstetric prevention is a separate indication.
  • Continue hydroxychloroquine in lupus unless a specific contraindication exists because withdrawal increases flare risk; monitor maternal disease and placental function rather than stopping treatment reflexively.
  • Certolizumab has minimal placental transfer and does not alter the infant live-vaccine schedule. Fc-containing TNF inhibitors continued late can require deferral of live vaccines to six months.
  • Prednisolone is the preferred systemic glucocorticoid when needed, ideally below 20 mg daily with steroid-sparing therapy, while monitoring diabetes, pressure, infection and adrenal risk.
  • Breastfeeding compatibility is not identical to pregnancy compatibility: hydroxychloroquine, sulfasalazine, azathioprine, tacrolimus, prednisolone and TNF inhibitors are generally compatible, while methotrexate, mycophenolate, leflunomide and JAK inhibitors are not.
  • Document a postpartum plan before delivery: flare surveillance, thromboprophylaxis when indicated, medicine restart, wound and infection review, breastfeeding and the infant live-vaccine schedule.

Key red flags

Severe headache, visual disturbance, epigastric pain, hypertension, thrombocytopenia or increasing proteinuria requires urgent pre-eclampsia assessment even when lupus nephritis is also plausible.

Chest pain, unilateral leg swelling, sudden dyspnoea, hypoxaemia or haemoptysis requires emergency venous-thromboembolism assessment, particularly with antiphospholipid antibodies.

Fever, rigors, urinary or respiratory symptoms, painful rash or reduced fetal movement during immunosuppression needs same-day maternity and infection review.

Rising creatinine, active urine sediment, falling complement, increasing anti-dsDNA or systemic lupus features may indicate nephritis flare and needs joint renal-rheumatology care.

Fetal bradycardia or conduction abnormality in an anti-Ro or anti-La pregnancy requires urgent fetal-medicine assessment, not maternal steroid escalation without confirmation.

Pregnancy exposure to methotrexate, mycophenolate, leflunomide, cyclophosphamide, a JAK inhibitor or another incompatible medicine requires immediate specialist advice.

Severe postpartum headache, neurological deficit, chest symptoms, haemorrhage or hypertensive features remain emergencies because thrombosis and flare risk persists after birth.

Investigation priorities

01
First-line preconception disease assessmentFirst stepFirst line

Define whether activity and organ reserve are safe enough for pregnancy.

Management branches

Preconception first-lineStabilise disease on compatible treatment

A person with rheumatic disease plans pregnancy but is not yet pregnant.

  1. Assess activity and organ, thrombotic and obstetric history and aim for approximately six months of stable low disease activity before conception.
  2. Continue or introduce compatible hydroxychloroquine, sulfasalazine, azathioprine, calcineurin inhibitor or TNF treatment appropriate to the disease.
  3. Stop or wash out incompatible medicines at their exact interval and verify leflunomide elimination before attempts at conception.
Late biologic exposureProtect maternal control and plan infant vaccines

An Fc-containing biologic is needed beyond the gestation at which stopping would permit routine live vaccination.

  1. Continue treatment when maternal flare risk outweighs theoretical infant exposure and record the exact agent and final antenatal dose.
  2. Tell neonatology, primary care and the vaccination team to defer live vaccines until six months or the product-specific safe point.
  3. Use certolizumab when clinically appropriate if continuous TNF inhibition and an unaltered live-vaccine schedule are priorities.

Key medicines

HydroxychloroquineContinue 200–400 mg orally daily, keeping long-term dose at no more than 5 mg/kg actual body weight each day, throughout pregnancy and breastfeeding when clinically indicated.Continue retinal and renal risk review; assess QT or cardiac symptoms and do not stop reflexively at conception because loss of disease control can harm pregnancy.
Sulfasalazine with folic acidTitrate sulfasalazine to the effective rheumatology dose, commonly 2 g orally daily in divided doses, and give folic acid 5 mg orally daily during periconception and the first trimester.Monitor FBC, liver and renal function; review allergy, G6PD and male reversible oligospermia. Breastfeeding needs paediatric caution for a premature, jaundiced or G6PD-deficient infant.
Open full textbook →Answer 2 questions
Sources and review status8 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • BSR pregnancy prescribing guideline Part IConventional medicines, biologics, pregnancy, breastfeeding and paternal exposure.
  • BSR pregnancy prescribing guideline Part IIComorbidity medicines, analgesia, antihypertensives and anticoagulation context.
  • MHRA NSAID risks after 20 weeks of pregnancyOligohydramnios and ductal-constriction precautions.
  • NICE NG133 hypertension in pregnancy recommendationsPre-eclampsia recognition, aspirin prevention and maternal or fetal monitoring.
  • Hydroxychloroquine UK product informationDose and pregnancy, lactation, retinal and cardiac information.
  • Leflunomide UK product informationPregnancy contraindication, washout and level verification.
  • Adalimumab UK product informationPlacental exposure, infection and infant live-vaccine caution.
  • Cimzia UK product informationCertolizumab regimen, minimal placental transfer and infection safety.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem ·

Pre-eclampsia pattern

New hypertension after 20 weeks with proteinuria or maternal organ or placental dysfunction requires urgent maternity assessment and can coexist with lupus nephritis.

Antiphospholipid complication

Thrombosis, recurrent early loss, fetal death, severe placental insufficiency or early pre-eclampsia with persistent antibodies defines different APS treatment intensities.

Anti-Ro fetal signal

Fetal bradycardia or conduction delay between 16 and 26 weeks in an anti-Ro or anti-La pregnancy needs urgent fetal cardiology confirmation.

Postpartum flare or thrombosis

Increasing arthritis, rash, renal change, chest symptoms or unilateral swelling in the first weeks after birth should not be dismissed as normal recovery.

Content changes
Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom